新兴的抗高血压疗法和心血管,脏和代谢结果:孟德尔的随机化研究
Nhu Ngoc Le1, Tran Quoc Bao Tran1, John McClure1
1BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
European heart journal. Cardiovascular pharmacotherapy
|February 18, 2025
概括
新的抗高血压药物,如PDE5抑制剂和sGC刺激剂,在降低心血管和脏疾病风险方面显示出有前途. 需要进一步的临床试验来确认这些新兴疗法的疗效和安全性.
科学领域:
- 药物基因组学和心血管医学.
- 调查新型抗高血压药物类别及其对CKM结果的影响.
背景情况:
- 新兴的抗高血压药物类别提供了新的治疗途径.
- 固酶5型抑制剂 (PDE5i),可溶性酸环酶刺激剂 (sGCs),内甲素受体对抗剂 (ERA) 和血管素原抑制剂 (AGTis) 对心血管,脏和代谢 (CKM) 结果的长期影响需要阐明.
研究的目的:
- 探索PDE5i,sGCs,ERAs和AGTis对一系列CKM结果的影响.
- 评估这些新型药物类别在管理高血压和相关风险方面的潜力.
主要方法:
- 采用孟德尔随机化 (MR),基于摘要的MR (SMR) 和局部化分析.
- 利用大规模的全基因组关联研究 (GWAS) 和欧洲祖先的基因型-组织表达 (GTEx) 数据.
- 评估了与冠状动脉疾病 (CAD),心肌梗塞 (MI),缺血性中风,心房动 (AF),心力衰竭 (HF),2型糖尿病 (T2D) 和慢性病 (CKD) 的相关性.
主要成果:
- 在所有研究结果中,基因预测的缩血压 (SBP) 降低与风险降低相关.
- PDE5i显示了CAD和缺血性中风的风险降低.
- sGCs表现出对CAD,MI和CKD的保护作用.
- ERA和AGTI显示对CAD和缺血性中风具有保护作用.
- SMR和局部化分析支持GUCY1A3/PDE5A基因表达与CAD/MI风险之间的联系.
结论:
- PDE5i,sGC,ERA和AGTI显示出减轻心血管和风险的潜力.
- 这些发现凸显了针对性临床试验的必要性,以验证这些抗高血压疗法的疗效和安全性.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
474
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
474
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
457
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
457
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
573
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
403
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
403